Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Current Assets (2019 - 2026)

Pliant Therapeutics has reported Current Assets over the past 8 years, most recently at $174.9 million for Q1 2026.

  • Quarterly Current Assets fell 43.79% to $174.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $174.9 million through Mar 2026, down 43.79% year-over-year, with the annual reading at $196.4 million for FY2025, 45.77% down from the prior year.
  • Current Assets was $174.9 million for Q1 2026 at Pliant Therapeutics, down from $196.4 million in the prior quarter.
  • Over five years, Current Assets peaked at $588.2 million in Q1 2023 and troughed at $173.5 million in Q2 2022.
  • The 5-year median for Current Assets is $362.3 million (2024), against an average of $362.6 million.
  • Year-over-year, Current Assets soared 226.0% in 2023 and then crashed 45.77% in 2025.
  • A 5-year view of Current Assets shows it stood at $340.3 million in 2022, then skyrocketed by 48.54% to $505.5 million in 2023, then fell by 28.34% to $362.3 million in 2024, then crashed by 45.77% to $196.4 million in 2025, then dropped by 10.95% to $174.9 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Current Assets are $174.9 million (Q1 2026), $196.4 million (Q4 2025), and $245.6 million (Q3 2025).